Lantheus Receives FDA Approval for Enhanced Prostate Cancer Imaging Agent PYLARIFY TruVu

Key Facts

1Lantheus received FDA approval for PYLARIFY TruVu (piflufolastat F 18) injection.

2The new formulation aims to enable larger batches and greater patient availability.

3The product is an enhanced formulation of the market-leading PSMA PET imaging agent for prostate cancer.

Lantheus (LNTH) has announced that the U.S. Food and Drug Administration (FDA) has approved PYLARIFY TruVu, a new formulation of its leading PSMA PET imaging agent for prostate cancer. This enhanced formulation is specifically designed to improve manufacturing efficiency by enabling the production of larger batches. By scaling up production, the company aims to significantly increase patient access to this critical diagnostic tool while optimizing its operational supply chain. PYLARIFY TruVu maintains the high diagnostic performance of the original market-leading product while offering greater scalability. The approval marks a significant milestone for Lantheus as it seeks to solidify its dominant position in the oncology imaging market. Investors view this regulatory success as a positive catalyst for the company's long-term growth prospects and market share retention.